BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10805336)

  • 1. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
    Künig G; Leenders KL; Sanchez-Pernaute R; Antonini A; Vontobel P; Verhagen A; Günther I
    Ann Neurol; 2000 May; 47(5):644-8. PubMed ID: 10805336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease.
    Holthoff VA; Koeppe RA; Frey KA; Penney JB; Markel DS; Kuhl DE; Young AB
    Ann Neurol; 1993 Jul; 34(1):76-81. PubMed ID: 8390806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
    Antonini A; Leenders KL; Eidelberg D
    Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D2 receptor binding in dopa-responsive dystonia.
    Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
    Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
    Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
    Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates.
    Brandt J; Folstein SE; Wong DF; Links J; Dannals RF; McDonnell-Sill A; Starkstein S; Anders P; Strauss ME; Tune LE
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):20-7. PubMed ID: 1983772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men.
    Boileau I; Dagher A; Leyton M; Gunn RN; Baker GB; Diksic M; Benkelfat C
    Arch Gen Psychiatry; 2006 Dec; 63(12):1386-95. PubMed ID: 17146013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys.
    Ohnishi T; Hayashi T; Okabe S; Nonaka I; Matsuda H; Iida H; Imabayashi E; Watabe H; Miyake Y; Ogawa M; Teramoto N; Ohta Y; Ejima N; Sawada T; Ugawa Y
    Biol Psychiatry; 2004 Mar; 55(5):484-9. PubMed ID: 15023576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride.
    Antonini A; Leenders KL; Reist H; Thomann R; Beer HF; Locher J
    Arch Neurol; 1993 May; 50(5):474-80. PubMed ID: 8489403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.
    Vollenweider FX; Vontobel P; Oye I; Hell D; Leenders KL
    J Psychiatr Res; 2000; 34(1):35-43. PubMed ID: 10696831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study.
    Lingford-Hughes AR; Wilson SJ; Cunningham VJ; Feeney A; Stevenson B; Brooks DJ; Nutt DJ
    Psychopharmacology (Berl); 2005 Aug; 180(4):595-606. PubMed ID: 15864554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
    Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
    J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease.
    Reuter I; Tai YF; Pavese N; Chaudhuri KR; Mason S; Polkey CE; Clough C; Brooks DJ; Barker RA; Piccini P
    J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):948-51. PubMed ID: 18356253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GABA(A) receptor imaging with positron emission tomography in the human newborn: a unique binding pattern.
    Chugani HT; Kumar A; Muzik O
    Pediatr Neurol; 2013 Jun; 48(6):459-62. PubMed ID: 23668871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
    Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
    Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.